| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | L34 |
| WB Predicted band size | 13 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human RPL34 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于RPL34抗体的相关文献摘要，供参考：
---
1. **文献名称**: *RPL34 as a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma*
**作者**: Li et al. (2020)
**摘要**: 研究通过免疫组化(使用RPL34抗体)发现RPL34在肝癌组织中高表达，与患者预后不良相关，可能通过调控细胞周期促进肿瘤进展。
---
2. **文献名称**: *Ribosomal Protein L34 Modulates Apoptosis in Colon Cancer Cells*
**作者**: Smith et al. (2018)
**摘要**: 利用RPL34抗体进行Western blot和免疫荧光实验，证实敲低RPL34可诱导结肠癌细胞凋亡，提示其作为潜在治疗靶点。
---
3. **文献名称**: *RPL34 Antibody Validation for Ribosome Profiling Studies*
**作者**: Zhang & Wang (2019)
**摘要**: 本研究验证了多种核糖体蛋白抗体的特异性，包括RPL34抗体在斑马鱼模型中的适用性，为核糖体功能研究提供工具支持。
---
4. **文献名称**: *RPL34 Expression Correlates with Immune Infiltration in Breast Cancer*
**作者**: Chen et al. (2021)
**摘要**: 通过免疫组化(RPL34抗体)结合TCGA数据分析，发现RPL34高表达与乳腺癌微环境中免疫细胞浸润减少相关，可能影响肿瘤免疫逃逸。
---
**注**：以上文献名为虚拟示例，实际引用时需通过PubMed或Web of Science检索具体文献。
The RPL34 antibody is a research tool designed to detect ribosomal protein L34 (RPL34), a component of the 60S ribosomal subunit. Ribosomal proteins like RPL34 play essential roles in protein synthesis, ribosome assembly, and cellular homeostasis. RPL34 is evolutionarily conserved and contributes to the structural stability of the ribosome, facilitating interactions between rRNA and other ribosomal proteins. Dysregulation of ribosomal proteins, including RPL34. has been implicated in diseases such as cancer, where altered ribosome biogenesis ("ribosomopathies") may drive tumor progression or metastasis.
Antibodies targeting RPL34 are typically developed using immunogens derived from specific epitopes of the human RPL34 protein. These antibodies are validated for applications like Western blotting, immunofluorescence, and immunohistochemistry to study RPL34 expression, localization, and potential overexpression in pathological conditions. Some studies suggest RPL34 may serve as a biomarker in certain cancers, though its mechanistic role remains under investigation. Cross-reactivity with homologs in model organisms (e.g., mice, rats) is common due to high sequence conservation. Researchers often employ these antibodies to explore links between ribosomal dysfunction, cellular stress responses, and disease pathways. Validation steps, such as siRNA knockdown or knockout cell controls, are critical to confirm specificity given the shared homology among ribosomal proteins.
×
